Apyx Medical is projected to report third-quarter 2026 revenue of $13.29 million and a consensus loss per share of $0.07, while the current stock price of $2.61 trades significantly below the $6.50 average analyst price target.
Investors are primarily focused on the sales momentum of the Surgical Aesthetics segment, specifically the adoption rates of the Renuvion technology and the newer AYON Body Contouring System.
While the company recently outperformed expectations in the second quarter, management must now demonstrate sustained growth to meet its full-year 2026 revenue guidance of $59 million to $60 million.
The market remains attentive to Apyx's path toward profitability given its negative return on equity and the competitive landscape of the cosmetic surgery market.